705-09-9

Basic information

• Product Name: 2-Difluoromethyl-1H-benzoimidazole
• Synonyms: 1H-benzo[d]imidazole, 2-(difluoromethyl)-;2-(Difluoromethyl);1H-Benzimidazole,2-(difluoromethyl)-(9CI);2-Difluoromethyl-1H-benzoimidazole;2-(difluoromethyl)-1H-benzimidazole(SALTDATA: FREE);2-(Difluoromethyl)-1H-benzimidazole;2-(difluoroMethyl)-1H-1,3-benzodiazole;2-Difluoromethylbenzimidazole
• CAS NO: 705-09-9
• Molecular Formula: C₈H₆F₂N₂
• Molecular Weight: 168.14
• Product Categories: BENZIMIDAZOLE
• Mol File: 705-09-9.mol
• Article Data: 27

Chemical Properties

• Melting Point: 155.0 to 159.0 °C
• Boiling Point: 309.8 °C at 760 mmHg
• Flash Point: 141.1 °C
• Appearance: /
• Density: 1.366 g/cm³
• Vapor Pressure: 0.00114mmHg at 25°C
• Refractive Index: 1.595
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 10.43±0.10(Predicted)
• CAS DataBase Reference: 2-Difluoromethyl-1H-benzoimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Difluoromethyl-1H-benzoimidazole(705-09-9)
• EPA Substance Registry System: 2-Difluoromethyl-1H-benzoimidazole(705-09-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 705-09-9(Hazardous Substances Data)

Usage

Description

2-Difluoromethyl-1H-benzoimidazole is a chemical compound characterized by the molecular formula C8H6F2N2. It is a benzimidazole derivative distinguished by the presence of two fluorine atoms attached to the carbon in the 2-position of the benzene ring. This unique structural feature endows it with potential biological activities, making it a promising candidate for pharmaceutical research and drug development.

Uses

Used in Pharmaceutical Research and Drug Development:
2-Difluoromethyl-1H-benzoimidazole is utilized as a precursor in the synthesis of various pharmaceutical compounds due to its distinctive structure and potential biological activity. Its incorporation into new drug molecules may enhance their therapeutic properties, offering novel treatment options for various medical conditions.
Used in Chemical Industry:
In the chemical industry, 2-Difluoromethyl-1H-benzoimidazole may serve as a key intermediate in the production of specialty chemicals and materials. Its unique fluorinated structure could contribute to the development of new compounds with improved properties, such as increased stability or reactivity, for use in various applications.
Further studies are required to fully explore the potential uses and properties of 2-Difluoromethyl-1H-benzoimidazole in both the pharmaceutical and chemical industries, ensuring its safe and effective application in the development of innovative products and therapies.

InChI:InChI=1/C8H6F2N2/c9-7(10)8-11-5-3-1-2-4-6(5)12-8/h1-4,7H,(H,11,12)

Upstream product

• 381-73-7 Difluoroacetic acid 
• 95-54-5 1,2-diamino-benzene 
• 65864-64-4 trimethyl(difluoromethyl)silane 
• 86652-69-9 2-azido-4-(tert-butyl)-1-isocyanobenzene 
• 51-17-2 benzoimidazole 
• 186204-66-0 2-(difluoromethanesulfonyl)-1,3-benzothiazole 
• 933772-60-2 ethyl 4,4-difluoro-2-chloro-3-oxobutanonate 
• 359-38-6 2,2-difluoroacetamide 
• 433-53-4 difluoroacetic acid methyl ester 
• 454-31-9 ethyl difluoroacetate 
• 401-67-2 2,2-difluoroacetic anhydride 
• 93032-23-6 methyl 2,2-dibromo-3-oxo-4,4-difluorobutyrate 

Downstream Products

• 180797-75-5 N-methyl-2-(difluoromethyl)benzimidazole 
• 475111-38-7 4-(4-chloro-6-(2-(difluoromethyl)-1H-benzo[d]imidazole -1-yl)-1,3,5-triazin-2-yl)morpholine 
• 475110-96-4 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine 
• 1394072-81-1 (R)-2-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-5-(4-(methylsulfonyl)benzyl)-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine 
• 1416956-33-6 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-15-4 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-34-7 (R)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-36-9 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)propan-1-one 
• 1416956-16-5 (R)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-20-1 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate 
• 1359951-16-8 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-morpholin-4-yl-N-[(3S)-1-(2-phenylethyl)pyrrolidin-3-yl]pyrimidin-2-amine 
• 1013403-79-6 4-(4-aminophenyl)-2-(2-difluoromethylbenzimidazol-1-yl)-6-morpholinopyrimidine 
• 1013403-85-4 4-(4-aminophenyl)-2-(2-difluoromethylbenzimidazol-1-yl)-6-[(3S)-3-methylmorpholin-4-yl]pyrimidine 
• 1013403-35-4 2-(2-difluoromethylbenzimidazol-1-yl)-4-(3-hydroxymethylphenyl)-6-morpholinopyrimidine 

Relevant articles and documents

Silver-Enabled General Radical Difluoromethylation Reaction with TMSCF2H

A silver-mediated oxidative difluoromethylation of styrenes and vinyl trifluoroborates with TMSCF2H is reported for the first time. This method enables direct and facile access to CF2H-alkenes from abundant alkenes with excellent functional-group compatibility. Moreover, this Ag/TMSCF2H protocol could further enable a series of radical difluoromethylation reactions of a wide array of substrates, offering a generic and complementary platform for the construction of diversified C?CF2H bonds.

Process for production of DFMB derivatives

A process for the production of a compound of formula (III) which comprises a step of reacting a compound of formula (I) with an excess amount of a compound of formula (II) in absence of aromatic solvent, wherein n is 0, 1, 2, 3 or 4; X is NH, O or S; eac

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.